Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included i...

Descripción completa

Detalles Bibliográficos
Autores principales: Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694416/
https://www.ncbi.nlm.nih.gov/pubmed/19401696
http://dx.doi.org/10.1038/sj.bjc.6605030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694416/
https://www.ncbi.nlm.nih.gov/pubmed/19401696
http://dx.doi.org/10.1038/sj.bjc.6605030

Ejemplares similares